Repeated cross-sectional analysis of hydroxychloroquine deimplementation in the AHA COVID-19 CVD Registry
Abstract There is little data describing trends in the use of hydroxychloroquine for COVID-19 following publication of randomized trials that failed to demonstrate a benefit of this therapy. We identified 13,957 patients admitted for active COVID-19 at 85 U.S. hospitals participating in a national r...
Guardado en:
Autores principales: | Steven M. Bradley, Sophia Emmons-Bell, R. Kannan Mutharasan, Fatima Rodriguez, Divya Gupta, Gregory Roth, Ty J. Gluckman, Rashmee U. Shah, Tracy Y. Wang, Rohan Khera, Pamela N. Peterson, Sandeep Das |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/86e2f28a42fa4d5789e3d0e70e0830b6 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Irreducible Cognitive Phenomenology and the Aha! Experience
por: John Joseph Dorsch
Publicado: (2017) -
Protocol for DRAUP: a deimplementation programme to decrease routine chest radiographs after central venous catheter insertion
por: Christopher Carpenter, et al.
Publicado: (2021) -
Impact of CVD knowledge, risk perception, and barriers to healthcare on routine CVD management in Coimbatore, India
por: I. Balachandran, et al.
Publicado: (2015) -
Living with cardiovascular disease (CVD): Exploring the biggest challenges for people affected by CVD in the UK, and their use (or not) of online resources
por: Sarah-Ann Burger, et al.
Publicado: (2020) -
INCREASING STATIN USE IN DIABETICS FOR CVD PREVENTION
por: Karsh Gaurav, et al.
Publicado: (2021)